11 results on '"Tissue Engineering legislation & jurisprudence"'
Search Results
2. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
- Author
-
Buljovčić Z
- Subjects
- Biological Products therapeutic use, Chondrocytes transplantation, Clinical Trials as Topic legislation & jurisprudence, Europe, Genetic Therapy legislation & jurisprudence, Humans, Quality Control, Stem Cell Transplantation legislation & jurisprudence, Tissue Engineering legislation & jurisprudence, Biotechnology legislation & jurisprudence, Consumer Product Safety legislation & jurisprudence, Marketing legislation & jurisprudence, Therapies, Investigational
- Abstract
On 30 December 2008, the Regulation (EC) 1394/2007 on advanced therapy medicinal products (ATMPs) entered into force. Herewith the first EU-wide regulatory framework for ATMPs was established. It requires a central marketing authorisation application to the EMA (European Medicinal Agency). This new framework especially changes the code of regulatory practice for tissue engineered products (TEPs), as no registration procedure had been previously required for autologous TEPs. This also meant that no clinical proof of efficacy achieved by a pivotal clinical trial was necessary. Difficulties and their background as well as the vast requirements for product development that have to be addressed by small companies within a very short time frame are presented. Hereby, it is obvious that regulatory experience which is required to identify and implement the resulting implications was not in place yet and still had to be established. The lack of regulatory experience also resulted in difficulties with scientific advice preparation, expectations toward regulatory agencies, consultants, and transformation of regulatory requirements. Addressing the regulatory requirements within the transition period is even more difficult for entrepreneurs with products which are assigned for indications resulting in complex challenges to the trial design. Due to the enormous time pressure to generate data and due to the implied financial pressure, different adaptation strategies are evolving. In Germany the "hospital exemption" according to §4b AMG (German Medicinal Products Law) is of major importance. A reorientation toward acellular products and a slow down in development of new ATMP products is expected.
- Published
- 2011
- Full Text
- View/download PDF
3. [Regulatory framework of innovative therapies : From bench to bedside].
- Author
-
Walter C, Rohde B, Wicke DC, Pohler C, Lührmann A, and von der Leyen H
- Subjects
- Biotechnology legislation & jurisprudence, Genetic Therapy legislation & jurisprudence, Germany, Guidelines as Topic, Humans, Stem Cell Transplantation legislation & jurisprudence, Tissue Engineering legislation & jurisprudence, Clinical Trials as Topic legislation & jurisprudence, Drugs, Investigational therapeutic use, National Health Programs legislation & jurisprudence, Therapies, Investigational, Translational Research, Biomedical legislation & jurisprudence
- Abstract
Novel therapies, e.g., cell and gene therapy or tissue engineering, are summarized in the European Union as advanced therapy medicinal products (ATMPs). In terms of composition and product properties, ATMPs are highly complex, and given their multiple potential actions they are subject to continuously developing regulatory requirements. Due to promising basic research findings, there are high expectations by the society toward the therapeutic potential of ATMPs. It is of utmost importance to develop a scientifically sound preclinical and clinical development plan before entering into the first clinical trial. Due to the complex features of ATMPs, this development plan should be discussed early with the regulatory authorities to define the specifics and challenges of each individual product. For planning as well as operational realization of the initial clinical trial involving ATMPs, specific requirements that need to be addressed are discussed in this paper.
- Published
- 2011
- Full Text
- View/download PDF
4. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
- Author
-
Carr M
- Subjects
- Europe, Humans, Marketing of Health Services economics, Marketing of Health Services legislation & jurisprudence, Cell Transplantation economics, Cell Transplantation legislation & jurisprudence, European Union, Financial Support, Genetic Therapy economics, Genetic Therapy legislation & jurisprudence, Private Sector economics, Private Sector legislation & jurisprudence, Tissue Engineering economics, Tissue Engineering legislation & jurisprudence
- Abstract
On 15 December 2005, the European Medicines Agency (EMEA) launched an "SME Office" to provide financial and administrative assistance to micro-, small- and medium-sized enterprises (SMEs), with the aim of promoting innovation and the development of new human and veterinary medicinal products by SMEs. According to current EU definition of an SME, companies with fewer than 250 employees, and an annual turnover of not more than 50 million euro or an annual balance sheet total of not more than 43 million euro, are eligible for assistance from the SME Office. Incentives available from the EMEA for SMEs, include: Administrative and procedural assistance from SME Office within the Agency; Fee reductions (90%) for scientific advice and inspections; Fee exemptions for certain administrative services (excluding parallel distribution); Deferral of the fee payable for an application for marketing authorisation or related inspection until after the grant of the marketing authorisation; Conditional fee exemption where scientific advice followed and marketing application is unsuccessful; Assistance with translations of the product information documents. At the end of May 2009, more than 380 companies from 21 countries across the European Economic Area (EEA) had SME status assigned by the EMEA. The large majority of companies are developing medicinal products for human use, 16 are veterinary companies, 15 companies are developing products for both human and veterinary use and 38 are regulatory consultants. Since the SME initiative started the Agency has processed more than 130 requests for scientific advice with fee reductions totalling of 6.9 million euro. Regulatory assistance has been provided to more than 170 companies and 12 companies have benefited from the SME translation service. Stakeholders have acknowledged the significant role the SME Office now plays as a service provider. In the period between January 2006 and June 2009, 34 applications for marketing authorization from SME applicants were filed for medicinal products for human use. Current analysis shows SMEs to have a lower success rate compared to non-SME companies. Major objections for SMEs are particularly high in the area of quality. Although the SME initiative is still at an early stage, it is apparent from the experience gained with applications for marketing authorisation to date that it is important for companies to open up an early dialogue with the EMEA. Scientific advice should be sought early, proactively and comprehensively on key issues in development (quality, non-clinical, clinical) and follow-up advice should be sought as development proceeds. For advanced therapy medicinal products, the assistance available to SMEs will be reinforced in 2009, with the introduction of the certification process.
- Published
- 2010
- Full Text
- View/download PDF
5. CAT--the new committee for advanced therapies at the European Medicines Agency.
- Author
-
Celis P
- Subjects
- Advisory Committees legislation & jurisprudence, Certification legislation & jurisprudence, Clinical Trials as Topic legislation & jurisprudence, Europe, Humans, Cell Transplantation legislation & jurisprudence, Consumer Product Safety legislation & jurisprudence, Genetic Therapy legislation & jurisprudence, Marketing of Health Services legislation & jurisprudence, Quality Assurance, Health Care legislation & jurisprudence, Tissue Engineering legislation & jurisprudence
- Abstract
The Regulation on Advanced Therapies (Regulation (EC) 1394/2007) establishes a new scientific committee, the Committee for Advanced Therapies (CAT), at the European Medicines Agency. The CAT is composed of experts in the field of Advanced Therapy Medicinal Products (ATMPs)--gene and cell therapy and tissue engineered products--and is responsible for the evaluation of the marketing authorisation applications for this novel class of products. The CAT is also involved in all scientific advice on ATMPs and in two new regulatory procedures for ATMPs, the classification and the certification procedures. The CAT will also play a key role in early contacts with developers of ATMPs.
- Published
- 2010
- Full Text
- View/download PDF
6. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
- Author
-
Salmikangas P, Flory E, Reinhardt J, Hinz T, and Maciulaitis R
- Subjects
- Europe, Gene Transfer Techniques, Guidelines as Topic, Humans, Quality Assurance, Health Care legislation & jurisprudence, Cell Transplantation legislation & jurisprudence, Clinical Trials as Topic legislation & jurisprudence, Genetic Therapy legislation & jurisprudence, Marketing of Health Services legislation & jurisprudence, Tissue Engineering legislation & jurisprudence
- Abstract
The new era of regenerative medicine has led to rapid development of new innovative therapies especially for diseases and tissue/organ defects for which traditional therapies and medicinal products have not provided satisfactory outcome. Although the clinical use and developments of cell-based medicinal products (CBMPs) could be witnessed already for a decade, robust scientific and regulatory provisions for these products have only recently been enacted. The new Regulation for Advanced Therapies (EC) 1394/2007 together with the revised Annex I, Part IV of Directive 2001/83/EC provides the new legal framework for CBMPs. The wide variety of cell-based products and the foreseen limitations (small sample sizes, short shelf life) vs. particular risks (microbiological purity, variability, immunogenicity, tumourigenicity) associated with CBMPs have called for a flexible, case-by-case regulatory approach for these products. Consequently, a risk-based approach has been developed to allow definition of the amount of scientific data needed for a Marketing Authorisation Application (MAA) of each CBMP. The article provides further insight into the initial risk evaluation, as well as to the quality, non-clinical, and clinical requirements of CBMPs. Special somatic cell therapies designed for active immunotherapy are also addressed.
- Published
- 2010
- Full Text
- View/download PDF
7. Legal basis of the Advanced Therapies Regulation.
- Author
-
Jekerle V, Schröder C, and Pedone E
- Subjects
- Certification legislation & jurisprudence, Europe, Germany, Humans, Marketing of Health Services, Quality Assurance, Health Care legislation & jurisprudence, Cell Transplantation legislation & jurisprudence, Genetic Therapy legislation & jurisprudence, Tissue Engineering legislation & jurisprudence
- Abstract
Advanced therapy medicinal products consist of gene therapy, somatic cell therapy and tissue engineered products. Due to their specific manufacturing process and mode of action these products require specially tailored legislation. With Regulation (EC) No. 1394/2007, these needs have been met. Definitions of gene therapy, somatic cell therapy and tissue engineered products were laid down. A new committee, the Committee for Advanced Therapies, was founded, special procedures such as the certification procedure for small- and medium-sized enterprises were established and the technical requirements for Marketing Authorisation Applications (quality, non-clinical and clinical) were revised.
- Published
- 2010
- Full Text
- View/download PDF
8. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
- Author
-
Montag-Lessing T, Störmer M, Schurig U, Brachert J, Bubenzer M, Sicker U, Beshir R, Spreitzer I, Löschner B, Bache C, Becker B, and Schneider CK
- Subjects
- Drug Contamination prevention & control, Germany, Humans, Quality Assurance, Health Care legislation & jurisprudence, Biological Products standards, Biological Therapy standards, Cell Transplantation legislation & jurisprudence, Cell Transplantation standards, Consumer Product Safety legislation & jurisprudence, Consumer Product Safety standards, Drug Contamination legislation & jurisprudence, Sterilization legislation & jurisprudence, Tissue Engineering legislation & jurisprudence, Tissue Engineering standards
- Abstract
Today, sterility of parenteral drugs is practically guaranteed. Well-defined procedures in the pharmaceutical industry enable effective protection against contamination by bacteria and fungi. In contrast, problems regarding microbial safety of advanced therapy medicinal products (ATMPs), especially of cell therapeutics, are at best only partially solved. The latter should be understood as a challenge for manufacturers, regulators, and physicians. Many of the manufacturing principles mentioned above are not applicable in production of cell therapeutics. Sterility of source materials cannot be guaranteed and the hitherto known procedures for sterilization are, as a rule, not feasible. Thus, the sterility of the final product cannot be guaranteed. Considering the extremely short shelf life of many cell therapeutics, sometimes only a few hours, the results from established methods for sterility testing are often available too late. Furthermore, the sterility of a test sample does not indicate sterility of the whole product. In most cases, conventional methods for pyrogen testing are not applicable for ATMPs. This paper demonstrates relevant limitations regarding microbial safety and pyrogenicity. Possibilities to overcome these problems are discussed and some novel solutions are proposed.
- Published
- 2010
- Full Text
- View/download PDF
9. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
- Author
-
Dwenger A, Strassburger J, and Schwerdtfeger W
- Subjects
- Consumer Product Safety legislation & jurisprudence, Germany, Guidelines as Topic, Humans, Cell Transplantation legislation & jurisprudence, Genetic Therapy legislation & jurisprudence, National Health Programs legislation & jurisprudence, Tissue Engineering legislation & jurisprudence
- Abstract
Regulation (EC) No. 1394/2007 has created a new legal framework for advanced therapy medicinal products (gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products). The Regulation is directly applicable in the Member States of the European Union and, in principle, requires no incorporation into national law. However, the amendment of Directive 2001/83/EC, which results from Regulation (EC) No. 1394/2007, has created a need for incorporation into and amendment of the German Medicinal Products Act. This is one of the objectives of the 15th amendment of the German Medicinal Products Act. In particular, the definition "advanced therapy medicinal products" and the special provisions for advanced therapy medicinal products prepared on a non-routine basis, which are based on the special provisions contained in Art. 28 No. 2 of Regulation (EC) No. 1394/2007, are to be incorporated into the German Medicinal Products Act. These special provisions will be explained in detail.
- Published
- 2010
- Full Text
- View/download PDF
10. [Clinical trials with advanced therapy medicinal products].
- Author
-
Schüssler-Lenz M and Schneider CK
- Subjects
- Consumer Product Safety, Germany, Guidelines as Topic, Humans, Marketing of Health Services legislation & jurisprudence, Quality Assurance, Health Care legislation & jurisprudence, Treatment Outcome, Biological Products standards, Cell Transplantation legislation & jurisprudence, Clinical Trials as Topic legislation & jurisprudence, Genetic Therapy legislation & jurisprudence, Tissue Engineering legislation & jurisprudence
- Abstract
For advanced therapies, the same basic principles for assessment apply as for any other biotechnological medicinal product. Nevertheless, the extent of data for quality, safety, and efficacy can be highly specific. Until recently, advanced therapies were not uniformly regulated across Europe, e.g., tissue engineered products were regulated either as medicinal products or medical devices. Thus, for some products no data from clinical studies are available, e.g., for autologous chondrocyte products. The draft guideline on Good Clinical Practice for clinical trials with advanced therapies describes specific additional requirements, e.g., ensuring traceability. Most clinical studies with advanced therapies in Germany are still in early phase I or II trials with highly divergent types of products and clinical indications. The Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMEA) has been established to meet the scientific and regulatory challenges with advanced therapies.
- Published
- 2010
- Full Text
- View/download PDF
11. [From basic research to the clinic. Regulations for preclinical and clinical studies with stem cells].
- Author
-
Steinhoff G, Tiedemann G, Thalheimer M, and Ho AD
- Subjects
- Adult, Ethics Committees ethics, Ethics Committees legislation & jurisprudence, Ethics, Research, Genetic Therapy ethics, Genetic Therapy legislation & jurisprudence, Germany, Hematopoietic Stem Cell Transplantation ethics, Hematopoietic Stem Cell Transplantation legislation & jurisprudence, Hematopoietic Stem Cells cytology, Humans, Stem Cell Transplantation ethics, Stem Cell Transplantation legislation & jurisprudence, Tissue Engineering ethics, Tissue Engineering legislation & jurisprudence, Embryo Research ethics, Embryo Research legislation & jurisprudence, Embryonic Stem Cells
- Abstract
The discovery of human embryonic stem cells at the end of 1998 had a strong influence on the development of stem cell research and led to controversial discussions. The first therapeutic application of adult blood stem cells began after their discovery in 1963 and was accepted as an authorized therapy in the early 1980s. The way from basic research to therapeutic use needed about 20 years and was also discussed in a controversial way similar to the discussions of today. The regulatory environment at that time, however, allowed a quick translation of the results from basic research to the clinic. Today many new stem cell therapies for a multitude of diseases are under development. Their clinical realization is regulated by the AMG (Arzneimittelgesetz). For nonclinical research as well as for clinical research, specific regulations are enacted to guarantee a structured and safe launch. Time, know how and money for planning, request for authorization and conduction of a clinical trial should not be underestimated. For clinical application of stem cell products authorization by the proper authorities is mandatory.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.